BOSTON, Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET.

A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.

About Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact

Hannah Deresiewicz, 212-362-1200
EVP, Managing Director, Precision AQ
hannah.deresiewicz@precisionaq.com

(PRNewsfoto/Elevation Oncology)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302236283.html

SOURCE Elevation Oncology

Copyright 2024 PR Newswire

Elevation Oncology (NASDAQ:ELEV)
過去 株価チャート
から 9 2024 まで 10 2024 Elevation Oncologyのチャートをもっと見るにはこちらをクリック
Elevation Oncology (NASDAQ:ELEV)
過去 株価チャート
から 10 2023 まで 10 2024 Elevation Oncologyのチャートをもっと見るにはこちらをクリック